Validated GC–MS analysis for the determination of residual fentanyl in applied Durogesic® reservoir and Durogesic® D-Trans® matrix transdermal fentanyl patches - ScienceDirect

Toxicological implications of the delivery of fentanyl from gel extracted from a commercial transdermal reservoir patch - ScienceDirect

Validated GC-MS analysis for the determination of residual fentanyl in applied Durogesic (R) reservoir and Durogesic (R) D-Trans (R) matrix transdermal fentanyl patches

Evaluation of in vitro/in vivo correlations for three fentanyl transdermal delivery systems using in vitro skin permeation testing and human pharmacokinetic studies under the influence of transient heat application - ScienceDirect

FENTANYL TRANSDERMAL SYSTEM 25 mcg/hr, 50 mcg/hr, 75 mcg/hr, 100 mcg/hr CII Full Prescribing Information Rx only FOR USE IN OPIOID-TOLERANT PATIENTS ONLY

Predicting transdermal fentanyl delivery using physics-based simulations for tailored therapy

PDF) Evaluation of the Single- and Multiple-Dose Pharmacokinetics of Fentanyl Buccal Soluble Film in Normal Healthy Volunteers

Transdermal patches: history, development and pharmacology - Pastore - 2015 - British Journal of Pharmacology - Wiley Online Library

Figure 1 from A randomized, open, parallel group, multicenter trial to investigate analgesic efficacy and safety of a new transdermal fentanyl patch compared to standard opioid treatment in cancer pain.

Frontiers Predicting Transdermal Fentanyl Delivery Using Mechanistic Simulations for Tailored Therapy